Denufosol
Clinical data | |
---|---|
Other names | INS37217 2'-Desoxycytidine (5')tetraphospho(5')uridine |
Routes of administration | Inhalation |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Denufosol (
FEV1 (forced expiratory volume in one second) at the week 48 endpoint as compared to placebo.[2]
As of 2011, no additional clinical studies are being conducted with the compound.
The drug was also investigated for the treatment of retinal detachment and other retinal diseases, but trials were terminated in 2006.[3]
Application
In Phase III studies, denufosol was orally inhaled by patients with cystic fibrosis three times a day using a jet nebulizer. To be effective, it had to reach the deeper parts of the lung (bronchioles), making it unsuitable for children under five years of age.[4]
Mechanism of action
Cystic fibrosis is characterised by a defect of the
P2Y2 subtype of purinergic receptors which via its associated G protein leads to activation of alternative chloride channel. Activating this alternate chloride channel theoretically increases ion transport in cystic fibrosis patients which compensates the effects caused by the non-functioning CFTR.[5]
Chemistry
Denufosol consists of two nucleosides (composed of a nucleobase and a sugar each), deoxycytidine and uridine, linked on their sugars by four units of phosphoric acid. It is used in form of its tetrasodium salt.[citation needed]
References
- PMID 21169471.
- ^ "Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis". Archived from the original on 2012-03-22. Retrieved 2011-04-03.
- ^ Clinical trial number NCT00083967 for "Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment" at ClinicalTrials.gov
- ^ Spreitzer H (14 March 2011). "Neue Wirkstoffe – Denufosol". Österreichische Apothekerzeitung (in German) (6/2011): 10.
- PMID 18276176.